Kindlin 3 Monoclonal Antibody (OTI2G2), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA526932-Each-of-1 | In Stock | ₹ 52,198.50 |
PIMA526932 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 52,198.50
GST (18%): ₹ 9,395.73
Total Price: ₹ 61,594.23
Antigen
Kindlin 3
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3
Gene Accession No.
Q86UX7
Gene Symbols
Fermt3
Immunogen
Human recombinant protein fragment corresponding to amino acids 259-528 of FERMT3 produced in E.coli
Quantity
100μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG2b
Applications
Immunohistochemistry (Paraffin), Western Blot
Clone
OTI2G2
Conjugate
Unconjugated
Gene
Fermt3
Gene Alias
C79673; fermitin family homolog 3; fermitin family homolog 3 (Drosophila); fermitin family member 3; Fermt3; Kind3; kindlin 3; Kindlin3; Kindlin-3; MGC10966; MIG-2; MIG2B; MIG2-like protein; RGD1310168; UNC-112 related protein 2; UNC112C; unc-112-related protein 2; URP2; URP2SF
Host Species
Mouse
Purification Method
Affinity Chromatography
Regulatory Status
RUO
Gene ID (Entrez)
83706
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Related Products
Description
- The three KINDLINs are a novel family of focal adhesion proteins, localizing to integrin adhesion sites
- The KINDLIN proteins are composed of a centrally located FERM domain interrupted by a pleckstrin homology (PH) domain
- KINDLIN1 and KINDLIN2 have been shown to play an essential role in integrin-mediated adhesion and spreading
- In contrast to the widely expressed KINDLIN1 and KINDLIN2, KINDLIN3 is restricted to hematopoietic cells and is particularly abundant in megakaryocytes and platelets
- Several reports describe a transcriptional misregulation of KINDLINs in various types of cancer
- A recent study demonstrates that KINDLIN3 is essential for platelet integrin activation and subsequent integrin outside-in signaling, suggesting it may serve as a potential target for the design of therapeutics aimed at specifically disrupting integrin activation in platelets and leukocytes.